"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

Scott Whitaker sent a letter to HHS calling for staff cuts at the FDA to be reversed, arguing patient care and U.S.

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for ...